| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases | Sarah de Crescenzo | 03/26/20 | San Francisco |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies | Sarah de Crescenzo | 03/20/20 | San Francisco |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Culture Biosciences Adds $15M for New Software, Bioreactor Expansion | Gareth Macdonald | 03/05/20 | San Francisco |
| Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors | Sarah de Crescenzo | 03/04/20 | San Francisco |
| Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics | Frank Vinluan | 03/03/20 | San Francisco |
| National Xconomy Awards Now Accepting Nominations for the Best in Biotech | Editors | 03/03/20 | National |
| Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven | Frank Vinluan | 03/02/20 | San Francisco |
| ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers | Sarah de Crescenzo | 03/02/20 | San Francisco |
| Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic | Frank Vinluan | 03/02/20 | Boston |
| Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies | Sarah de Crescenzo | 02/28/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK | Frank Vinluan | 02/27/20 | New York |
| Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing | Sarah de Crescenzo | 02/27/20 | National |
| With Foamix Merger Weeks Away, Menlo Itching Drug Fails a Phase 2 Test | Frank Vinluan | 02/26/20 | San Francisco |
| NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data | Sarah de Crescenzo | 02/24/20 | San Francisco |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal | Sarah de Crescenzo | 02/20/20 | Seattle |
| Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug | Frank Vinluan | 02/20/20 | San Francisco |
| Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials | Sarah de Crescenzo | 02/19/20 | National |
| Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test | Sarah de Crescenzo | 02/18/20 | San Francisco |
